https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-fiscal-2026-results-report BiopharmaWatch en 2026-09-22T00:00:00.000Z Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026 https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-acquisition-marea-therapeutics BiopharmaWatch en 2026-09-17T13:26:00.000Z Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement https://www.biopharmawatch.com/news/VNRX/volitionrx-detectseps-launch-france BiopharmaWatch en 2026-09-17T13:17:00.000Z VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France https://www.biopharmawatch.com/news/LEXX/lexaria-updates-financial-position BiopharmaWatch en 2026-09-17T13:13:29.000Z Lexaria Updates Financial Position https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-1-2-million-offering BiopharmaWatch en 2026-09-17T13:10:00.000Z Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering https://www.biopharmawatch.com/news/POCI/precision-optics-engineering-order-satellite-customer BiopharmaWatch en 2026-09-17T13:00:00.000Z Precision Optics Announces Initial Engineering Order from New Satellite Optical Communications Customer https://www.biopharmawatch.com/news/CELZ/creative-medical-expands-ultrasome-patent-portfolio BiopharmaWatch en 2026-09-17T13:00:00.000Z Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing https://www.biopharmawatch.com/news/CODX/co-diagnostics-participate-who-unitaid-unaids-meeting BiopharmaWatch en 2026-09-17T13:00:00.000Z Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026 https://www.biopharmawatch.com/news/SGRY/surgery-partners-sale-idaho-falls-facilities-intermountain-health BiopharmaWatch en 2026-09-17T13:00:00.000Z Surgery Partners Completes Sale of Ownership Interests in Idaho Falls Facilities to Intermountain Health; Updates Guidance to Include Impact of the Transaction https://www.biopharmawatch.com/news/NTHI/neonc-eliminates-dilution-risk-clinical-advancements BiopharmaWatch en 2026-09-17T12:54:00.000Z NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-appoints-robert-spiegel-board BiopharmaWatch en 2026-09-17T12:42:00.000Z Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-engages-executives-drug-development BiopharmaWatch en 2026-09-17T12:32:00.000Z Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth https://www.biopharmawatch.com/news/TELO/telomir-zinc-visual-function-amd BiopharmaWatch en 2026-09-17T12:30:00.000Z Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD) https://www.biopharmawatch.com/news/QTI/qt-imaging-appoints-dr-mark-winkler-cmo BiopharmaWatch en 2026-09-17T12:30:00.000Z QT Imaging Appoints Imaging Industry Veteran Dr. Mark Winkler as Chief Medical Officer https://www.biopharmawatch.com/news/ABBV/abbvie-phase-3-etentamig-results-ims-2026 BiopharmaWatch en 2026-09-17T12:30:00.000Z AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting https://www.biopharmawatch.com/news/FBLG/fibrobiologics-private-placement-closing BiopharmaWatch en 2026-09-17T12:30:00.000Z FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-phase-3-trial-sgt-610-gorlin-syndrome BiopharmaWatch en 2026-09-17T12:30:00.000Z Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-hope3-presentation-wms-2026 BiopharmaWatch en 2026-09-17T12:30:00.000Z Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress https://www.biopharmawatch.com/news/MIRA/mira-pharmaceuticals-ketamir-2-phase-2a-cipn BiopharmaWatch en 2026-09-17T12:30:00.000Z MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review https://www.biopharmawatch.com/news/LTRN/lantern-pharma-open-medicine-ai-webinar-september-2026 BiopharmaWatch en 2026-09-17T12:20:00.000Z Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23 https://www.biopharmawatch.com/news/VNRX/volitionrx-launch-detectseps-program-france BiopharmaWatch en 2026-09-17T12:17:00.000Z VolitionRx Participates in Launch of DETECSEPS Program in France https://www.biopharmawatch.com/news/CING/cingulate-smart-launch-indegene-summit BiopharmaWatch en 2026-09-17T12:05:00.000Z Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma https://www.biopharmawatch.com/news/NTHI/neonc-technologies-redeems-series-a-preferred-stock BiopharmaWatch en 2026-09-17T12:00:33.000Z NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution https://www.biopharmawatch.com/news/CRL/charles-river-rapid-cell-banking-innovation BiopharmaWatch en 2026-09-17T12:00:00.000Z Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines https://www.biopharmawatch.com/news/BIAF/bioaffinity-hong-kong-patent-cypath-lung-diagnostic BiopharmaWatch en 2026-09-17T12:00:00.000Z bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-skin-quality-improvements BiopharmaWatch en 2026-09-17T12:00:00.000Z Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications https://www.biopharmawatch.com/news/ADPT/nccn-guidelines-update-multiple-myeloma-clonoseq BiopharmaWatch en 2026-09-17T12:00:00.000Z Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ® https://www.biopharmawatch.com/news/VTAK/catheter-precision-locket-expansion-latin-america BiopharmaWatch en 2026-09-17T12:00:00.000Z Catheter Precision Expands LockeT Commercialization Across Latin America Following Successful Launch in Brazil https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-stifel-2026-forum BiopharmaWatch en 2026-09-17T12:00:00.000Z Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-virtual-kol-event-lam-001 BiopharmaWatch en 2026-09-17T12:00:00.000Z Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026 https://www.biopharmawatch.com/news/COAG/hemab-therapeutics-phase-1-trial-hmb-003 BiopharmaWatch en 2026-09-17T12:00:00.000Z Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding https://www.biopharmawatch.com/news/ELAN/elanco-bofa-securities-global-healthcare-conference-2026 BiopharmaWatch en 2026-09-17T11:57:00.000Z Elanco to Participate in BofA Securities Global Healthcare Conference 2026 https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-evoke-platform-radial-ai-native-os BiopharmaWatch en 2026-09-17T11:50:00.000Z Firefly Neuroscience’s Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial’s AI-Native Operating System for Brain Medicine https://www.biopharmawatch.com/news/CMND/clearmind-fda-psychedelic-hearing-2026 BiopharmaWatch en 2026-09-17T11:42:00.000Z Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C. https://www.biopharmawatch.com/news/NUVB/nuvation-bio-fda-approval-ibtrozi-taletrectinib BiopharmaWatch en 2026-09-17T11:30:00.000Z Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-pedmark-results-siope-2026 BiopharmaWatch en 2026-09-17T11:30:00.000Z Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026 https://www.biopharmawatch.com/news/KALA/kala-bio-yenvy-truong-advisory-team BiopharmaWatch en 2026-09-17T11:30:00.000Z KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team https://www.biopharmawatch.com/news/NVO/orbis-novo-nordisk-drug-discovery-partnership BiopharmaWatch en 2026-09-17T11:00:00.000Z Orbis Medicines Enters Multi-Target Drug Discovery Partnership with Novo Nordisk Worth up to USD 1.4 Billion https://www.biopharmawatch.com/news/CVS/aetna-expands-bundled-oncology-prior-authorizations BiopharmaWatch en 2026-09-17T11:00:00.000Z Aetna expands bundled oncology prior authorizations, easing provider burden and accelerating member access to care https://www.biopharmawatch.com/news/PLSM/pulsenmore-expands-fertility-platform-uk BiopharmaWatch en 2026-09-17T11:00:00.000Z Pulsenmore Expands Its Fertility Platform into the UK https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-psych-congress-2026-presentations BiopharmaWatch en 2026-09-17T11:00:00.000Z Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026 https://www.biopharmawatch.com/news/KMDA/cdc-reports-increase-rabies-exposures-kamada-supply-kedrab BiopharmaWatch en 2026-09-17T11:00:00.000Z CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand https://www.biopharmawatch.com/news/INDV/indivior-pharmaceuticals-special-cash-dividend BiopharmaWatch en 2026-09-17T11:00:00.000Z Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-resubmission-fda-anaphylm BiopharmaWatch en 2026-09-17T11:00:00.000Z Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film https://www.biopharmawatch.com/news/TLSA/tiziana-signs-mou-with-kaimrc-for-clinical-trial BiopharmaWatch en 2026-09-17T11:00:00.000Z Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center https://www.biopharmawatch.com/news/GANX/gain-therapeutics-roth-healthcare-conference BiopharmaWatch en 2026-09-17T11:00:00.000Z Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference https://www.biopharmawatch.com/news/BMY/bms-sotyktu-efficacy-safety-psoriatic-arthritis BiopharmaWatch en 2026-09-17T10:59:00.000Z Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years https://www.biopharmawatch.com/news/ACH/accendra-health-names-kenneth-gardner-smith-ceo BiopharmaWatch en 2026-09-17T10:30:00.000Z Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth https://www.biopharmawatch.com/news/AEMD/aethlon-north-immunology-merger-atopic-dermatitis BiopharmaWatch en 2026-09-17T10:30:00.000Z Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis https://www.biopharmawatch.com/news/OSTX/os-therapies-fda-alignment-project-orbis-ost-her2 BiopharmaWatch en 2026-09-17T10:00:00.000Z OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program https://www.biopharmawatch.com/news/YI/111-inc-receives-preliminary-acquisition-proposal BiopharmaWatch en 2026-09-17T08:25:00.000Z 111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company https://www.biopharmawatch.com/news/IPHA/innate-pharma-first-half-2026-business-update BiopharmaWatch en 2026-09-17T05:00:00.000Z Innate Pharma Reports First Half 2026 Business Update and Financial Results https://www.biopharmawatch.com/news/IPHA/sobi-innate-partnership-effective-closing-conditions BiopharmaWatch en 2026-09-17T03:28:00.000Z Sobi and Innate announce partnership is now effective following completion of closing conditions https://www.biopharmawatch.com/news/A/agilent-announces-cash-dividend-25-5-cents BiopharmaWatch en 2026-09-16T22:59:00.000Z CORRECTING and REPLACING Agilent Announces Cash Dividend of 25.5 Cents per Share https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-inducement-grants-cmo BiopharmaWatch en 2026-09-16T21:33:00.000Z AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/LGVN/longeveron-elpis-ii-trial-results-hlhs BiopharmaWatch en 2026-09-16T21:27:00.000Z Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) https://www.biopharmawatch.com/news/HALO/halozyme-proposed-offering-convertible-senior-notes BiopharmaWatch en 2026-09-16T20:30:00.000Z Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 https://www.biopharmawatch.com/news/PNTG/pennant-acquires-mainplace-senior-living-orange-california BiopharmaWatch en 2026-09-16T20:30:00.000Z Pennant Acquires Real Estate of Mainplace Senior Living in Orange, California https://www.biopharmawatch.com/news/BRVE/braveheart-bio-participate-stifel-cardiometabolic-forum BiopharmaWatch en 2026-09-16T20:30:00.000Z Braveheart Bio to Participate in Stifel Cardiometabolic Forum https://www.biopharmawatch.com/news/A/agilent-announces-quarterly-dividend-25-5-cents BiopharmaWatch en 2026-09-16T20:15:00.000Z Agilent Announces Cash Dividend of 25.5 Cents per Share https://www.biopharmawatch.com/news/MDAI/spectral-ai-deepview-system-burn-indication-srbc BiopharmaWatch en 2026-09-16T20:15:00.000Z Spectral AI Showcases DeepView® System for Burn Indication and KOL Research at Southern Regional Burn Conference https://www.biopharmawatch.com/news/BIIB/biogen-third-quarter-2026-financial-results BiopharmaWatch en 2026-09-16T20:06:00.000Z Biogen to Report Third Quarter 2026 Financial Results October 28, 2026 https://www.biopharmawatch.com/news/GOSS/gossamer-bio-appoints-greg-ciongoli-board BiopharmaWatch en 2026-09-16T20:01:00.000Z Gossamer Bio Appoints Greg Ciongoli to Board of Directors https://www.biopharmawatch.com/news/AVLN/avalyn-appoints-robert-meyer-board-directors BiopharmaWatch en 2026-09-16T20:01:00.000Z Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors https://www.biopharmawatch.com/news/IPHA/innate-sobi-partnership-effective-closing-conditions BiopharmaWatch en 2026-09-16T20:00:00.000Z Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions https://www.biopharmawatch.com/news/MOH/molina-donates-trauma-informed-care-iowa-youth BiopharmaWatch en 2026-09-16T18:00:00.000Z The MolinaCares Accord and Molina Healthcare of Iowa Donate $50,000 to Expand Trauma-Informed Care for Iowa Youth https://www.biopharmawatch.com/news/TMO/thermo-fisher-junior-innovators-challenge-2026-finalists BiopharmaWatch en 2026-09-16T16:03:00.000Z Thirty Inspiring Middle School Scientists and Engineers Named Finalists in the 2026 Thermo Fisher Scientific Junior Innovators Challenge https://www.biopharmawatch.com/news/WAT/everlywell-partnership-waters-hpv-screening-tool BiopharmaWatch en 2026-09-16T14:00:00.000Z Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients https://www.biopharmawatch.com/news/DNA/ginkgo-datapoints-partnership-tunelab-ai-drug-discovery BiopharmaWatch en 2026-09-16T13:52:00.000Z Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data https://www.biopharmawatch.com/news/KTO/cashu-research-initiates-coverage-k2-gold-corporation BiopharmaWatch en 2026-09-16T13:49:00.000Z Cashu Research Initiates Coverage on K2 Gold Corporation (KTO) https://www.biopharmawatch.com/news/NXGL/nexgel-announces-investor-update-call-date BiopharmaWatch en 2026-09-16T13:29:00.000Z NEXGEL Announces Date for Investor Update Call https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-ai-chemical-risk-screening BiopharmaWatch en 2026-09-16T13:25:00.000Z Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI https://www.biopharmawatch.com/news/IBO/impact-biomedical-merger-zoar-ltd-registration-filing BiopharmaWatch en 2026-09-16T13:20:00.000Z Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited) https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-dr-carmen-guerra-advisory-board BiopharmaWatch en 2026-09-16T13:15:00.000Z Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board https://www.biopharmawatch.com/news/SYK/stryker-foot-ankle-innovation-aofas-2026 BiopharmaWatch en 2026-09-16T13:06:00.000Z Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™ https://www.biopharmawatch.com/news/BIO/bio-rad-fireside-chat-bernstein-forum BiopharmaWatch en 2026-09-16T13:00:00.000Z Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum https://www.biopharmawatch.com/news/MLSS/milestone-scientific-compuflo-development-partner BiopharmaWatch en 2026-09-16T13:00:00.000Z Milestone Scientific Announces Pain and Spine Specialists and Dr. Sudhir Rao as CompuFlo® Development Partner and Advisor https://www.biopharmawatch.com/news/NRXS/neuraxis-medical-coverage-policy-expansion BiopharmaWatch en 2026-09-16T13:00:00.000Z NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives https://www.biopharmawatch.com/news/CVS/cvs-health-wear-your-heart-bandage-art-contest BiopharmaWatch en 2026-09-16T13:00:00.000Z CVS Health Launches National "Wear Your HeART" Bandage Art Contest https://www.biopharmawatch.com/news/NTHI/neonc-insider-buying-fda-focus BiopharmaWatch en 2026-09-16T12:46:00.000Z NeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA https://www.biopharmawatch.com/news/AUNA/auna-host-2026-investor-day-october-22 BiopharmaWatch en 2026-09-16T12:45:00.000Z Auna to Host 2026 Investor Day on October 22, 2026 https://www.biopharmawatch.com/news/CODX/co-diagnostics-readygo-ebola-testing-collaboration BiopharmaWatch en 2026-09-16T12:45:00.000Z Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola https://www.biopharmawatch.com/news/GILD/gilead-accelerates-global-access-lenacapavir-hiv-prevention BiopharmaWatch en 2026-09-16T12:30:00.000Z Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention https://www.biopharmawatch.com/news/CAH/cardinal-health-lawsuits-dismissed-pharmacy-customers BiopharmaWatch en 2026-09-16T12:30:00.000Z Cardinal Health Loses Multiple "Product Return" Lawsuits Against Pharmacy Customers and Pays Attorneys' Fees to Settle Sanctions Motion for Frivolous Litigation https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-public-offering-pricing BiopharmaWatch en 2026-09-16T12:30:00.000Z Cuprina Holdings (Cayman) Limited Announces Pricing of $4.97 million Public Offering https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-avim-therapy-hrx-live-2026 BiopharmaWatch en 2026-09-16T12:30:00.000Z Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026 https://www.biopharmawatch.com/news/AMIX/autonomix-medical-appoints-sandra-kalter-board BiopharmaWatch en 2026-09-16T12:30:00.000Z Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors https://www.biopharmawatch.com/news/OGEN/oragenics-cmo-present-ipac-rs-2026-nasal-innovation-forum BiopharmaWatch en 2026-09-16T12:30:00.000Z Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum https://www.biopharmawatch.com/news/RVMD/propanc-prp-emt-reversal-ras-inhibitors BiopharmaWatch en 2026-09-16T12:30:00.000Z Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc. https://www.biopharmawatch.com/news/EQ/equillium-participate-stifel-2026-immunology-forum BiopharmaWatch en 2026-09-16T12:30:00.000Z Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum https://www.biopharmawatch.com/news/OPTH/optimi-health-phase-3-mdma-ptsd-trial BiopharmaWatch en 2026-09-16T12:25:00.000Z Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-first-patient-phase-2-trial BiopharmaWatch en 2026-09-16T12:15:00.000Z MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial https://www.biopharmawatch.com/news/VIVS/vivosim-namkind-drug-toxicity-data-eurotox-2026 BiopharmaWatch en 2026-09-16T12:05:00.000Z VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs https://www.biopharmawatch.com/news/DGX/medicare-lab-payment-cuts-survey-results BiopharmaWatch en 2026-09-16T12:03:00.000Z Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics https://www.biopharmawatch.com/news/NTHI/neonc-executives-invest-stock-after-positive-phase-2a-results BiopharmaWatch en 2026-09-16T12:00:39.000Z NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results https://www.biopharmawatch.com/news/HYPR/medtechwomen-hyperfine-ceo-maria-sainz-award BiopharmaWatch en 2026-09-16T12:00:00.000Z MedtechWOMEN Names Hyperfine CEO Maria Sainz Winner of 2026 Ferolyn Powell Leadership Award https://www.biopharmawatch.com/news/TWST/twist-bioscience-lilly-tunelab-antibody-drug-discovery BiopharmaWatch en 2026-09-16T12:00:00.000Z Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery https://www.biopharmawatch.com/news/ADGM/adagio-medical-first-patient-ide-study-vclas-ultra BiopharmaWatch en 2026-09-16T12:00:00.000Z Adagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLAS™ Ultra System for Ventricular Tachycardia at Banner – University Medical Center Phoenix https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-regains-nasdaq-compliance BiopharmaWatch en 2026-09-16T12:00:00.000Z Alzamend Neuro Regains Compliance with Nasdaq Listing Standards https://www.biopharmawatch.com/news/XCUR/exicure-nasdaq-extension-compliance-stockholders-equity BiopharmaWatch en 2026-09-16T12:00:00.000Z Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement https://www.biopharmawatch.com/news/ODTX/odyssey-therapeutics-stifel-2026-forum BiopharmaWatch en 2026-09-16T12:00:00.000Z Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum https://www.biopharmawatch.com/news/MYGN/myriad-genetics-appoints-vishal-sikri-evp-commercial BiopharmaWatch en 2026-09-16T12:00:00.000Z Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial https://www.biopharmawatch.com/news/STXS/stereotaxis-ai-automation-hrx-2026 BiopharmaWatch en 2026-09-16T11:59:00.000Z Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society’s HRX 2026 https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-art27-13-weight-loss-semaglutide BiopharmaWatch en 2026-09-16T11:30:00.000Z Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity https://www.biopharmawatch.com/news/CNSY/cerenome-appoints-samantha-fowlkes-commercial-sales BiopharmaWatch en 2026-09-16T11:30:00.000Z Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-uf-health-zevaskyn-activation BiopharmaWatch en 2026-09-16T11:30:00.000Z Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN® https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-warrant-exercise-7-million BiopharmaWatch en 2026-09-16T11:27:00.000Z Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds https://www.biopharmawatch.com/news/ROVA/altrova-health-debt-settlement-announcement BiopharmaWatch en 2026-09-16T11:07:00.000Z Altrova Health Announces Proposed Debt Settlement https://www.biopharmawatch.com/news/ACB/aurora-cannabis-business-update-acquisition-safari-flower BiopharmaWatch en 2026-09-16T11:05:00.000Z Aurora Cannabis Provides Business Update; Accretive Acquisition of Safari Flower Company and Leading European Performance Expected to Fuel International Growth in the Fiscal Second Quarter 2027 and Beyond https://www.biopharmawatch.com/news/EYE/rise-nano-optics-vision-council-2026-forum BiopharmaWatch en 2026-09-16T11:00:00.000Z Rise Nano Optics to Attend the Vision Council's 2026 Lab Leadership Forum https://www.biopharmawatch.com/news/XBIO/xenetic-santersus-share-exchange-agreement-net-therapeutics BiopharmaWatch en 2026-09-16T11:00:00.000Z Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics https://www.biopharmawatch.com/news/ALKS/alkermes-appoints-anne-whitaker-board-directors BiopharmaWatch en 2026-09-16T11:00:00.000Z Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors https://www.biopharmawatch.com/news/IDXX/idexx-acquires-covetai-veterinary-workflow-intelligence BiopharmaWatch en 2026-09-16T11:00:00.000Z IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence https://www.biopharmawatch.com/news/INSM/insmed-global-day-of-good-2026 BiopharmaWatch en 2026-09-16T11:00:00.000Z Insmed Expands Community Impact During Fifth Annual Global Day of Good https://www.biopharmawatch.com/news/KLRA/kailera-therapeutics-september-investor-conferences BiopharmaWatch en 2026-09-16T11:00:00.000Z Kailera Therapeutics to Participate in September Investor Conferences https://www.biopharmawatch.com/news/NRXS/neuraxis-participate-lytham-partners-fall-2026-investor-conference BiopharmaWatch en 2026-09-16T11:00:00.000Z NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference https://www.biopharmawatch.com/news/FATE/fate-therapeutics-acr-convergence-2026-presentations BiopharmaWatch en 2026-09-16T11:00:00.000Z Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 https://www.biopharmawatch.com/news/VTRS/viatris-approval-wakix-japan-narcolepsy-osas BiopharmaWatch en 2026-09-16T10:59:00.000Z Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome https://www.biopharmawatch.com/news/CMPS/compass-pathways-td-cowen-summit-participation-2026 BiopharmaWatch en 2026-09-16T10:30:00.000Z Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 https://www.biopharmawatch.com/news/MDT/medtronic-fda-clearance-ligasure-ras-maryland-instrument BiopharmaWatch en 2026-09-16T10:30:00.000Z Medtronic announces FDA clearance for LigaSure™ RAS Maryland instrument on the Hugo™ RAS system https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-coronavirus-drug-candidate-ind-studies BiopharmaWatch en 2026-09-16T09:00:00.000Z Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies https://www.biopharmawatch.com/news/NVNO/envenno-medical-ceo-rob-berman-video-series BiopharmaWatch en 2026-09-16T08:50:00.000Z enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series https://www.biopharmawatch.com/blog/phase-2-3-readouts-week-of-2026-09-14 BiopharmaWatch en 2026-09-16T07:15:26.171Z Upcoming Phase 3 Readouts: Key Insights and Analysis https://www.biopharmawatch.com/news/BIIB/leqembi-pen-approval-japan-alzheimers-treatment BiopharmaWatch en 2026-09-16T06:00:31.000Z LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease https://www.biopharmawatch.com/news/SNN/smith-nephew-plc-announces-result-cash-tender-offer-2030-bonds BiopharmaWatch en 2026-09-16T05:45:00.000Z Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds https://www.biopharmawatch.com/news/BBNX/beta-bionics-public-offering-pricing BiopharmaWatch en 2026-09-16T03:56:00.000Z Beta Bionics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants https://www.biopharmawatch.com/news/OILS/nextleaf-leadership-transition-sam-kassem-ceo BiopharmaWatch en 2026-09-15T23:50:00.000Z Nextleaf Announces Leadership Transition and Strategic Review; Sam Kassem Appointed Interim CEO https://www.biopharmawatch.com/news/CARL/carlsmed-patent-infringement-lawsuit-degen-medical BiopharmaWatch en 2026-09-15T23:00:00.000Z Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical https://www.biopharmawatch.com/news/RPRX/royalty-pharma-donation-blood-cancer-united-tap BiopharmaWatch en 2026-09-15T20:36:51.000Z Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program https://www.biopharmawatch.com/news/NEOG/neogen-first-quarter-earnings-release-date BiopharmaWatch en 2026-09-15T20:30:00.000Z Neogen Announces First-Quarter Earnings Release Date https://www.biopharmawatch.com/news/EHC/encompass-health-rehabilitation-hospital-lower-providence BiopharmaWatch en 2026-09-15T20:30:00.000Z Encompass Health Rehabilitation Hospital of Lower Providence now open in Pennsylvania https://www.biopharmawatch.com/news/RPRX/blood-cancer-united-royalty-pharma-donation BiopharmaWatch en 2026-09-15T20:30:00.000Z Blood Cancer United Announces $7.5 Million Gift From Royalty Pharma to Expand Therapy Acceleration Program https://www.biopharmawatch.com/news/CODX/co-diagnostics-press-conference-sept-16-2026 BiopharmaWatch en 2026-09-15T20:15:00.000Z Co-Diagnostics to Hold Press Conference https://www.biopharmawatch.com/news/CRON/cronos-host-2026-investor-day-kingsville-ontario BiopharmaWatch en 2026-09-15T20:15:00.000Z Cronos to Host 2026 Investor Day at its Cronos GrowCo Facility in Kingsville, Ontario https://www.biopharmawatch.com/news/BBNX/beta-bionics-public-offering-125-million BiopharmaWatch en 2026-09-15T20:13:00.000Z Beta Bionics Announces Proposed Public Offering of $125.0 Million of Common Stock https://www.biopharmawatch.com/news/TPST/tempest-exclusive-option-license-cd7-targeted-car-t BiopharmaWatch en 2026-09-15T20:05:11.000Z Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-regulatory-clinical-appointments BiopharmaWatch en 2026-09-15T20:05:00.000Z Jasper Therapeutics Announces Key Regulatory and Clinical Appointments https://www.biopharmawatch.com/news/NRXP/nrxp-fda-update-preservative-free-ketamine BiopharmaWatch en 2026-09-15T19:11:00.000Z NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine https://www.biopharmawatch.com/news/HIMS/hims-and-hers-class-action-lawsuit BiopharmaWatch en 2026-09-15T19:08:00.000Z Shareholders who lost money in shares of acquired Hims & Hers Health, Inc. (NYSE: HIMS) should contact Wolf Haldenstein Immediately https://www.biopharmawatch.com/news/PZZA/papa-johns-shareholder-lawsuit-wolf-haldenstein BiopharmaWatch en 2026-09-15T18:54:00.000Z Shareholders who lost money in shares of acquired Papa John's International, Inc. (NASDAQ: PZZA) should contact Wolf Haldenstein Immediately https://www.biopharmawatch.com/news/SNN/smith-nephew-tender-offer-2030-bonds BiopharmaWatch en 2026-09-15T18:00:00.000Z Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds https://www.biopharmawatch.com/news/PRCT/lawsuit-notice-procept-biorobotics-investors BiopharmaWatch en 2026-09-15T17:15:00.000Z LAWSUIT NOTICE: NASDAQ: PRCT Investors who lost money with PROCEPT BioRobotics Corporation shares should contact the Shareholders Foundation https://www.biopharmawatch.com/news/FEED/envue-medical-nasdaq-listing-update BiopharmaWatch en 2026-09-15T16:45:00.000Z ENvue Medical Provides Nasdaq Listing Update